NO20084307L - Heterocykliske GPCR agonister - Google Patents

Heterocykliske GPCR agonister

Info

Publication number
NO20084307L
NO20084307L NO20084307A NO20084307A NO20084307L NO 20084307 L NO20084307 L NO 20084307L NO 20084307 A NO20084307 A NO 20084307A NO 20084307 A NO20084307 A NO 20084307A NO 20084307 L NO20084307 L NO 20084307L
Authority
NO
Norway
Prior art keywords
gpcr agonists
heterocyclic
agonists
heterocyclic gpcr
treatment
Prior art date
Application number
NO20084307A
Other languages
English (en)
Norwegian (no)
Inventor
Matthew Colin Thor Fyfe
Lisa Sarah Bertram
Martin James Procter
Geoffrey Martyn Williams
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606913A external-priority patent/GB0606913D0/en
Priority claimed from GB0700112A external-priority patent/GB0700112D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of NO20084307L publication Critical patent/NO20084307L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20084307A 2006-04-06 2008-10-15 Heterocykliske GPCR agonister NO20084307L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0606913A GB0606913D0 (en) 2006-04-06 2006-04-06 Compounds
GB0700112A GB0700112D0 (en) 2007-01-04 2007-01-04 Compounds
PCT/GB2007/050183 WO2007116229A1 (en) 2006-04-06 2007-04-05 Heterocyclic gpcr agonists

Publications (1)

Publication Number Publication Date
NO20084307L true NO20084307L (no) 2008-10-28

Family

ID=38227799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084307A NO20084307L (no) 2006-04-06 2008-10-15 Heterocykliske GPCR agonister

Country Status (12)

Country Link
US (1) US20090221639A1 (enExample)
EP (1) EP2013201B1 (enExample)
JP (1) JP2009532453A (enExample)
KR (1) KR20080109075A (enExample)
AU (1) AU2007235673A1 (enExample)
BR (1) BRPI0710839A2 (enExample)
CA (1) CA2646676A1 (enExample)
MX (1) MX2008012814A (enExample)
NO (1) NO20084307L (enExample)
NZ (1) NZ571869A (enExample)
WO (1) WO2007116229A1 (enExample)
ZA (1) ZA200809289B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0806498A2 (pt) * 2007-01-04 2014-04-22 Prosidion Ltd Agonistas gpcr piperidina
CL2008000018A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
WO2008081208A1 (en) * 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009034388A1 (en) 2007-09-10 2009-03-19 Prosidion Limited Compounds for the treatment of metabolic disorders
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010084512A1 (en) 2008-12-24 2010-07-29 Cadila Healthcare Limited Novel oxime derivatives
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
WO2011016470A1 (ja) 2009-08-05 2011-02-10 第一三共株式会社 スルホン誘導体
JP5546542B2 (ja) 2009-08-05 2014-07-09 第一三共株式会社 アミド誘導体
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AU2011311183B2 (en) 2010-10-08 2014-09-25 Cadila Healthcare Limited Novel GPR 119 agonists
NZ610145A (en) 2010-10-14 2015-02-27 Daiichi Sankyo Co Ltd Acylbenzene derivative having a hypoglycemic action and/or a β cell- or pancreas-protecting action
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
PH12014500251A1 (en) 2011-07-29 2014-03-17 Daiichi Sankyo Co Ltd N-hetero-ring-substituted amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013062837A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Piperidine derivatives useful as gpr119 agonists
HK1200824A1 (en) 2012-01-18 2015-08-14 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2880027B1 (en) 2012-08-02 2016-09-28 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032965A1 (en) * 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Oxadiazole derivative and medicinal composition thereof
US6699853B2 (en) * 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
IL149872A0 (en) * 1999-12-16 2002-11-10 Schering Corp Substituted imidazole neuropeptide y y5 receptor antagonists
ES2887054T3 (es) * 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
BRPI0418149A (pt) * 2003-12-24 2007-04-17 Prosidion Ltd derivados heterocìclicos como agonistas do receptor de gprc
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20090203676A1 (en) * 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists

Also Published As

Publication number Publication date
US20090221639A1 (en) 2009-09-03
MX2008012814A (es) 2008-10-17
BRPI0710839A2 (pt) 2011-08-23
WO2007116229A8 (en) 2007-12-27
NZ571869A (en) 2011-11-25
ZA200809289B (en) 2012-06-27
WO2007116229A1 (en) 2007-10-18
AU2007235673A1 (en) 2007-10-18
EP2013201B1 (en) 2012-07-25
EP2013201A1 (en) 2009-01-14
CA2646676A1 (en) 2007-10-18
JP2009532453A (ja) 2009-09-10
KR20080109075A (ko) 2008-12-16

Similar Documents

Publication Publication Date Title
NO20084364L (no) Azetidin derivater som G-protein koblet reseptor (GPR119) agonister
ATE523507T1 (de) Piperidin-gpcr-agonisten
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
WO2007116229A8 (en) Heterocyclic gpcr agonists
NO20080010L (no) GPCR-agonister
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
NO20080052L (no) G-Protein kopplede reseptoragonister
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
WO2007003961A3 (en) Gpcr agonists
JO2681B1 (en) Indole derivatives
NO20085257L (no) Purinonderivater som HM74a-agonister
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
UA97257C2 (en) Indole derivatives
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20065868L (no) Substituerte aryl- og heteroarylderivater som metabolisme- og profylkasemodulatorer og behandling av forstyrrelser forbundet med dette
MX2012000704A (es) Agonistas de gpr119.
NO20085099L (no) Puritonderivativer som HM74A agonister
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
NO20082445L (no) Neuropeptid-2 reseptor-agonister
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application